Home / Zinc Status in Human Immunodeficiency Virus Infection +

  • See also:  Zinc, Alcohol Damage, and Thyroid Function +

  • .

Original ⇒ HERE

ZINC STATUS IN HUMAN
IMMUNODEFICIENCY VIRUS INFECTION

.
© 2000 The American Society for Nutritional Sciences

  1. Marianna K. Baum2, 

  2. Gail Shor-Posner, and 

  3. Adriana Campa

Author Affiliations Center for Disease Prevention,

Department of Psychiatry and Behavioral Medicine,

University of Miami School of Medicine, Miami, FL 33136

 

  1. To whom correspondence should be addressed.

Abstract:

There is substantial evidence to support an important role for zinc in immune processes. Adequate zinc status is essential for T-cell division, maturation and differentiation; lymphocyte response to mitogens; programmed cell death of lymphoid and myeloid origins; gene transcription; and biomembrane function. Lymphocytes are one of the types of cells activated by zinc. Zinc is the structural component of a wide variety of proteins, neuropeptides, hormone receptors and polynucleotides.
Among the best known zinc-dependent hormones/enzymes are Cu, Zn superoxide dismutase, an enzyme component of the antioxidant defense system, and thymulin, which is essential for the formation of T-lymphocytes. In animals and humans, zinc deficiency results in rapid and marked atrophy of the thymus, impaired cell-mediated cutaneous sensitivity and lymphopenia. Primary and secondary antibody responses are reduced in zinc deficiency, particularly for those antigens that require T-cell help, such as those in heterologous red blood cells. In addition, antibody response and the generation of splenic cytotoxic T cells after immunization are reduced. Zinc also inhibits the production of tumor necrosis factor, which is implicated in the pathophysiology of cachexia and wasting in acquired immune deficiency syndrome.

Deficiency of zinc is most frequently evaluated by measuring plasma levels. Even though plasma zinc is an acute phase reactant that may change in response to metabolic alterations, plasma zinc levels react to dietary intake in a rapid and measurable manner (Gershwin et al. 1985, Keen 1990). Low plasma levels of zinc have been observed in congenital diseases such as sickle cell anemia (Ballester et al. 1986), Down’s syndrome (Licastro et al. 1992) and acrodermatitis enteropathica. Zinc deficiency also is characterized by decreased thymulin activity and impaired lymphocyte response to phytohemagglutinin (Chandra 1980, 1997). Zinc deficiency has been observed in acquired conditions, including malabsorption syndrome (McClain 1985), malnutrition (Keen 1990), cancer (Mocchegiani et al. 1994), alcoholism (Zarski et al. 1987), end-stage liver disease (Pescovitz et al. 1996), uremia (Mahajan et al. 1982) and chronic and acute infectious diseases such as human immunodeficiency virus (HIV)3 type 1 (HIV-1) infection (Ripa and Ripa 1995). Similarly, altered zinc levels in plasma, enzymes and neurons have been demonstrated in a number of disorders of the central nervous system (Ebadi et al. 1995). Low plasma zinc levels, either congenital or acquired, are associated with immune abnormalities, impaired healing processes and increased susceptibility to infections.

Previous SectionNext Section

Zinc status and HIV-1

The significance of zinc status in HIV-1 infection has not been fully elucidated. Zinc promotes multimerization and enhances enzymatic activity of viral integrase and its “zinc fingers” (Lee et al. 1997). Zinc also is a component of HIV-1 nucleocapsid proteins (Berthoux et al. 1997, Darlix et al. 1995, Zheng et al. 1996). In addition, HIV-1 transactivating protein (Tat) has a unique cysteine-rich region with zinc binding properties (Huang and Wang 1996) and has a high binding affinity for zinc (Frankel et al. 1988). Zinc utilization by the HIV-1 for gene expression, multimerization and integration characterizes HIV-1 as a zinc-dependent virus, which may at least in part explain the low plasma zinc levels frequently observed in HIV-1–infected patients (Mocchegiani et al. 1995).

Consistent with this characterization of the virus, Tang et al. (1993, 1996) reported an association between elevated intakes of zinc and faster disease progression and death in HIV-1–infected homosexual/bisexual men. This cohort had a relatively high intake of zinc, and changes in zinc intake or plasma zinc status over time were not considered. It should also be noted that an excessive intake of zinc (300 mg/d, 20 times the recommended daily allowance) results in significant immune impairment in healthy adult men (Chandra 1985). In addition, excessive intake of zinc may interfere with copper and iron utilization and affect HDL cholesterol concentrations and monocyte function (Fosmire 1990, Schlesinger et al. 1993), all of which may contribute to HIV-1 disease progression.

Previous SectionNext Section

Zinc status and the immune system in HIV infection

Patients with acquired immune deficiency syndrome (AIDS) exhibit clinical symptoms similar to those associated with zinc deficiency, including immune deficiencies, impaired taste and appetite, decreased food intake, gastrointestinal malfunction with diarrhea, alopecia, epithelial lesions and hypogonadism and hypospermia (King and Keen 1994, Odeh 1992).

Low concentrations of zinc are prevalent in HIV-1–infected male and female drug users as well as other HIV-1–infected cohorts (Baum et al. 1995 and 1997a, ⇓, Beach et al. 1992). Such low concentrations of plasma zinc have been linked with disease progression, independent of baseline CD4 cell count, lymphocyte concentrations and age- and calorie-adjusted dietary intake (Falutz et al. 1988, Graham et al. 1991). Of particular importance, low plasma zinc levels have been associated with a threefold increased risk of HIV-1–related death in HIV-1–seropositive drug users (Baum et al. 1997b).

Zinc has an important role in inhibiting tumor necrosis factor (TNF) (Flieger et al. 1989), which has been implicated in the pathophysiology of AIDS, including wasting (Beutler and Cerami 1987). An increase in TNF levels has been reported as the disease advances to AIDS (Reddy et al. 1988, Rosenberg and Fauci 1989). In addition, zinc deficiency reduces the secretion by T cells of interleukin-4 (IL-4), a growth factor for T-cell helpers (Dowd et al. 1986). In turn, IL-4 may significantly inhibit the production of TNF by monocytes (Hart et al. 1989), which reinforces the potential role of adequate zinc status in preventing disease progression in HIV-1 infection (Rosenberg and Fauci 1990).

Cu, Zn superoxide dismutase (Cu-Zn SOD) is a zinc-dependent enzyme that is essential for the antioxidant defense system. Zinc deficiency in HIV-1 infection may compromise the production of Cu-Zn SOD and adversely affect the antioxidant response to the overproduction of free radicals and lipid peroxides observed early in the disease (Favier et al. 1994). In vitro, Cu-Zn SOD has been demonstrated to reduce HIV-1 replication (Edeas et al. 1996), whereas oxidative stress stimulates the replication of HIV-1 (Favier et al. 1994).

Previous SectionNext Section

Zinc supplementation and the immune system

Zinc supplementation has been demonstrated to increase the efficiency of the immune system in a number of study populations, including marasmic infants (Castillo-Duran et al. 1987), children recovering from malnutrition (Golden and Golden 1981), patients with sickle cell anemia (Prasad and Cossack 1984) and children with Down’s syndrome (Chiriciolo et al. 1993, Licastro et al. 1992). In addition, improvement in immunologic responses has been demonstrated with zinc treatment in obese children and adolescents (Chandra and Kutty 1980). An advantageous effect of the use of zinc in individuals with cold symptoms has been reported by some (Al-Nakib et al. 1987, Eby et al. 1984, Godfrey et al. 1992, Mossad et al.1996), but not all (Douglas et al. 1987, Farr et al. 1987, Smith et al. 1989, Weismann et al. 1990), investigations. Zinc supplementation in elderly subjects produced the restoration, at least partially, of nutritional and thymic status with no adverse effects (Boukaiba et al. 1993). An improvement in immune response has also been demonstrated with zinc therapy in zinc-deficient elderly individuals (Cossack 1989), although not in healthy elderly individuals (Bogden et al. 1988, Swanson et al. 1988).

Few zinc supplementation studies have been conducted in HIV/AIDS patients. Zinc administration in HIV-1 infection stage III and IV adult patients treated with zidovudine has been demonstrated to stabilize weight and to increase CD4 cell count as well as plasma levels of zinc-bound thymulin. A marked reduction in opportunistic infections in the zinc-treated group was also demonstrated in this study, especially in Pneumocystis carinii and Candida infections (Mocchegiani et al. 1995). This is in accord with our findings demonstrating a zidovudine-induced effect on nutritional parameters with zinc-adequate, but not zinc-deficient, subjects exhibiting a significant increase in the response of peripheral blood lymphocytes to mitogens (Baum et al. 1991).

In summary, evidence to date indicates that adequate amounts of zinc are essential to maintain the integrity of the immune system and that HIV-1–infected individuals are a population particularly susceptible to zinc deficiency. On the other hand, excessive zinc may stimulate HIV-1. The association between zinc deficiency and decreased survival in HIV-1–infected individuals indicates the need to carefully consider therapeutic options. Moreover, with the advent of new antiretroviral therapies that may significantly alter the natural history of HIV/AIDS, the prevalence of zinc deficiency and the potential of interventions in HIV-infected individuals may change dramatically, generating new challenges.

Previous SectionNext Section

Footnotes

  • ↵1 Presented at the international workshop “Zinc and Health: Current Status and Future Directions,” held at the National Institutes of Health in Bethesda, MD, on November 4–5, 1998. This workshop was organized by the Office of Dietary Supplements, NIH and cosponsored with the American Dietetic Association, the American Society for Clinical Nutrition, the Centers for Disease Control and Prevention, Department of Defense, Food and Drug Administration/Center for Food Safety and Applied Nutrition and seven Institutes, Centers and Offices of the NIH (Fogarty International Center, National Institute on Aging, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Drug Abuse, National Institute of General Medical Sciences and the Office of Research on Women’s Health). Published as a supplement to The Journal of Nutrition. Guest editors for this publication were Michael Hambidge, University of Colorado Health Sciences Center, Denver; Robert Cousins, University of Florida, Gainesville; Rebecca Costello, Office of Dietary Supplements, NIH, Bethesda, MD; and session chair, Craig McClain, University of Kentucky, Lexington.

  • ↵3 Abbreviations: AIDS, acquired immune deficiency syndrome; HIV, human immunodeficiency virus; TNF, tissue necrosis factor; Cu-Zn SOD, Cu, Zn superoxide dismutase.

Previous Section

LITERATURE CITED

  1. ↵ 

    Al-Nakib, W., Higgins, P. G., Barrow, I., Batstone, G. & Tyrrell, D. A. (1987) Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. J. Antimicrob. Chemother. 20:893-901.

    Abstract/FREE Full Text

  2. ↵ 

    Baum, M. K., Shor-Posner, G., Zhang, G., Lai, H., Quesada, J., Miguez-Burbano, M., Fletcher, M. A., Sauberlich, H. & Page, J. B. (1997a) HIV-1 infection in women is associated with severe nutritional deficiencies. J. Acquir. Immune. Defic. Syndr. Hum. Retro. 16:272-278.

    Medline

  3. ↵ 

    Baum, M. K., Shor-Posner, G., Lai, S., Zhang, G., Lai, H., Fletcher, M. A., Sauberlich, H. & Page, J. B. (1997b) High risk of HIV-related mortality is associated with selenium deficiency. J. Acquir. Immune. Defic. Syndr. Hum. Retro. :15-374.

  4. ↵ 

    Baum, M. K., Shor-Posner, G., Lu, Y., Rosner, B., Sauberlich, H. E., Fletcher, M. A., Szapocznik, J., Eisdorfer, C., Buring, J. E. & Hennekens, C. H. (1995) Micronutrients and HIV-1 disease progression. AIDS 9:1051-1056.

    CrossRefMedline

  5. ↵ 

    Baum, M. K., Javier, J. J., Mantero-Atienza, E., Beach, R. S., Fletcher, M. A., Sauberlich, H. E., Feaster, D. & Shor-Posner, G. (1991) Zidovudine-associated adverse reactions in a longitudinal study of asymptomatic HIV-1-infected homosexual males. J. Acquir. Immune. Defic. Syndr. Hum. Retro. 4:1218-1226.

     ↵ 

  6. Ballester, O. F., Abdallah, M. & Prasad, A. S. (1986) Lymphocyte subpopulation abnormalities in sickle cell anemia: a distinctive pattern from that of AIDS. Am. J. Haematol. 21:23-27.

     CrossRefMedline

  7. ↵ 

    Beach, R. S., Mantero-Atienza, E., Shor-Posner, G., Javier, J. J., Szapocznik, J., Morgan, R., Sauberlich, H. E., Cornwell, P. E., Eisdorfer, C. & Baum, M. K. (1992) Specific nutrient abnormalities in asymptomatic HIV-1 infection. AIDS 6:701-708.

     Medline

  8. ↵ 

    Berthoux, L., Pechoux, C., Ottman, M., Morel, G. & Darlix, J. L. (1997) Mutations in the N-terminal domain of human immunodeficiency virus type 1 nucleocapsid protein affect virion core structure and proviral DNA synthesis. J Virol 71:6973-6981.

    Abstract/FREE Full Text

  9. ↵ 

    Beutler, B. & Cerami, A. (1987) Cachectin: more than a tumor necrosis factor. N. Engl. J. Med. 316:479-485.

     ↵ 

  10. Bogden, J. D., Oleske, J. M., Lavenhar, M. A., Munves, E. M., Kemp, F. W., Bruening, K. S., Holding, K. J., Denny, T. N., Guarino, M. A. & Krieger, L. M. (1988) Zinc and immunocompetence in elderly people: effects of zinc supplementation for 3 months. Am. J. Clin. Nutr. 48:655-663.

    Abstract/FREE Full Text

  11. ↵ 

    Boukaiba, N., Flament, C., Acher, S., Chappuis, P., Piau, A., Fusselier, M., Dardenne, M. & Lemonnier, D. (1993) A physiological amount of zinc supplementation: effects on nutritional, lipid, and thymic status in an elderly population. Am. J. Clin. Nutr. 57:566-572.

     Abstract/FREE Full Text

  12. ↵ 

    Castillo-Duran, C., Heresi, G., Fisberg, M. & Uauy, R. (1987) Controlled trial of zinc supplementation during recovery from malnutrition: effects on growth and immune function. Am. J. Clin. Nutr. 45:602-608.

     Abstract/FREE Full Text

  13. Champion, S., Imhof, B. S., Savagner, P. & Thiery, J. P. (1986) The embryonic thymus produces chemotactic peptides involved in the homing of hemopoietic precursors. Cell 44:781-790.

     CrossRefMedline

  14. ↵ 

    Chandra, R. K. (1997) Nutrition and the immune system: an introduction. Am. J. Clin. Nutr. 66:460.S-463.S.

     Abstract/FREE Full Text

  15. ↵ 

    Chandra, R. K. (1985) Trace element regulation of immunity and infection. J. Am. Coll. Nutr. 4:5-16.

    Medline

  16. ↵ 

    Chandra, R. K. & Kutty, K. M. (1980) Immunocompetence in obesity. Acta Paediatr. Scand. 69:25-30.

     Medline

  17. ↵ 

    Chandra, R. K. (1980) Acrodermatitis enteropathica: zinc levels and cell-mediated immunity. Pediatrics 66:789-791.

    Abstract/FREE Full Text

  18. ↵ 

    Chiricolo, M., Musa, A. R., Monti, D., Zannotti, M. & Franceschi, C. (1993) Enhanced DNA repair in lymphocytes of Down syndrome patients: the influence of zinc nutritional supplementation. Mutat. Res. 295:105-111.

    CrossRefMedline

  19. ↵ 

    Cossack, Z. T. (1989) T-lymphocyte dysfunction in the elderly associated with zinc deficiency and subnormal nucleoside phosphorylase activity: effect of zinc supplementation. Eur. J. Cancer Clin. Oncol. 25:973-976.

    CrossRefMedline

  20. ↵ 

    Darlix, J. L., Lapadat-Tapolsky, M., de Rocquigny, H. & Roques, B. P. (1995) First glimpses at structure-function relationships of the nuclecapsid protein of retroviruses. J. Mol. Biol. 254:523-537.

    CrossRefMedline

  21. ↵ 

    Douglas, R. M., Miles, H. B., Moore, B. W., Ryan, P. & Pinnock, C. B. (1987) Failure of effervescent zinc acetate lozenges to alter the course of upper respiratory tract infection in Australian adults. Antimicrob. Agents Chemother.31:1263-1265.

    Abstract/FREE Full Text

  22. ↵ 

    Dowd, P. S., Kelleher, J. & Guillou, P. J. (1986) T-lymphocyte subsets and interleukin-2 production in zinc deficient rats. Br. J. Nutr. 55:59-65.

    CrossRefMedline

  23. ↵ 

    Ebadi, M., Iversen, P. L., Hao, R., Cerutis, D. R., Rojas, P., Happe, H. K., Murrin, L. C. & Pfeiffer, R. F. (1995) Expression and regulation of brain metallothionein. Neurochem. Int. 27:1-22.

    CrossRefMedline

  24. ↵ 

    Eby, G. A., Davis, D. R. & Halcomb, W. W. (1984) Reduction in duration of common cold by zinc gluconate lozenges in a double-blind study. Antimicrob. Agents Chemother. 25:20-24.

    Abstract/FREE Full Text

  25. ↵ 

    Edeas, M. A., Peltier, E., Claise, C., Khalfoun, Y. & Lindenbaum, A. (1996) Immunocytochemical study of uptake of exogenous carrier-free copper-zinc superoxidase dismutase by peripheral blood lymphocytes. Cell Mol. Biol. (Noisy-le-grand) 42:1137-1143.

    Medline

  26. Fabris, N. & Mocchegiani, E. (1995) Zinc, human diseases and aging. Aging (Milano) 7:77-93.

    Medline

  27. ↵ 

    Falutz, J., Tsoukas, C. & Gold, P. (1988) Zinc as a cofactor in human immunodeficiency virus-induced immunosupression. J. Am. Med. Assoc.259:2850-2851.

    CrossRefMedline

  28. ↵ 

    Farr, B. M., Conner, E. M., Betts, R. F., Oleske, J., Minnefor, A. & Gwaltney, J. M. (1987) Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds. Antimicrob. Agents Chemother.31:1183-1187.

    Abstract/FREE Full Text

  29. ↵ 

    Favier, A., Sappey, C., Leclerc, P., Faure, P. & Micoud, M. (1994) Antioxidant status and lipid peroxidation in patients infected with HIV. Chem. Biol. Ineract.91:165-180.

  30. Fee, J. A. & Bull, C. (1986) Steady-state kinetic studies of superoxide dismutases: saturative behavior of the copper- and zinc-containing protein. J. Biol. Chem. 261:13000-13005.

    Abstract/FREE Full Text

  31. ↵ 

    Flieger, D., Riethmuller, G. & Ziegler-Heitbrock, H.W.L. (1989) Zn2+ inhibits both tumor necrosis factor-mediated DNA framentation and cytolysis. Int. J. Cancer 44:315-319.

    CrossRefMedline

  32. ↵ 

    Fosmire, G. J. (1990) Zinc toxicity. Am. J. Clin. Nutr. 51:225-227.

    Abstract/FREE Full Text

  33. ↵ 

    Frankel, A. D., Bredt, D. S. & Pabo, C. O. (1988) Tat protein from human immunodeficiency virus forms a metal linked dimer. Science (Washington DC)240:70-73.

    Abstract/FREE Full Text

  34. ↵ 

    Gershwin, M. E., Beach, R. S. & Hurley, L. S. (1985) Tat protein from human immunodeficiency virus forms a metal linked dimer. Nutrition and ImmunityAcademic Press Orlando, FL.

  35. ↵ 

    Golden, M. H. & Golden, B. E. (1981) Effect of zinc supplementation on the dietary intake, rate of weight gain, and energy cost of tissue deposition in children recovering from severe malnutrition. Am. J. Clin. Nutr. 34:900-908.

    Abstract/FREE Full Text

  36. ↵ 

    Godfrey, J. C., Conant-Sloane, B., Smith, D. S., Turco, J. H., Mercer, N. & Godfrey, N. J. (1992) Zinc gluconate and the common cold: a controlled clinical study. J. Int. Med. Res. 20:234-246.

     Abstract/FREE Full Text

  37. ↵ 

    Graham, N.M.H., Sorenson, D., Odaka, N., Brookmayer, R., Chan, D., Willett, W. C., Morns, J. S. & Saah, A. J. (1991) Relationship of serum copper and zinc levels to HIV-1 seropositivity and progression to AIDS. J. Acquir. Immune Defic. Syndr. 4:976-980.

  38. ↵ 

    Hart, P. H., Vitti, G. F, Burgess, D. R., Witty, G. A., Piccoli, D. S. & Hamilton, T. A. (1989) Potential anti-inflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor α, interleukin 1, and prostaglandin E2. Proc. Natl. Acad. Sci. U.S.A. 86:3803-3807.

    Abstract/FREE Full Text

  39. ↵ 

    Huang, H. W. & Wang, K. T. (1996) Structural characterization of the metal binding site in the cysteine-rich region of HIV-1 Tat protein. Biochem. Biophys. Res. Commun. 227:615-621.

    CrossRefMedline

  40. ↵ 

    Keen, C. L. (1990) Zinc deficiency and immune function. Annu. Rev. Nutr.10:415-431.

    CrossRefMedline

  41. ↵ 

    King, J. C. & Keen, C. L. (1994) Zinc. Shils, M. E. Olson, J. A. Shike, M. eds. Modern Nutrition in Health and Disease 8th ed. Lea & Febiger Philadelphia.

  42. ↵ 

    Lee, P. S., Xiao, J., Knutson, J. R., Lewis, M. S. & Han, M. K. (1997) Zn2+promotes the self-association of human immunodeficiency virus type-1 integrase in vitro. Biochemistry 36:173-180.

    CrossRefMedline

  43. ↵ 

    Licastro, F., Mocchegiani, E., Zannotti, M., Arena, G., Masi, M. & Fabris, N. (1992) Zinc affects the metabolism of thyroid hormones in children with Down’s syndrome: normalization of thyroid stimulating hormone and of reversal triiodothryonine plasmic levels by dietary zinc supplementation. Int. J. Neurosci.65:259-268.

    CrossRefMedline

  44. ↵ 

    Mahajan, S. K., Prasad, A. S., Rabbani, P, Briggs, W. A. & McDonald, F. D. (1982) Zinc deficiency: a reversible complication of uremia. Am. J. Clin. Nutr.36:367-383.

  45. ↵ 

    McClain, C. S. (1985) Zinc metabolism in malabsorption syndromes. J. Am. Coll. Nutr. 4:49-64.

    Medline

  46. ↵ 

    Mocchegiani, E., Veccia, S., Ancarani, F., Scalise, G. & Fabris, N. (1995) Benefit of oral zinc supplementation as an adjunct to zidovudine (AZT) therapy against opportunistic infections in AIDS. Int. J. Immunopharmacol. 17:719-727.

    CrossRefMedline

  47. ↵ 

    Mocchegiani, E., Paolucci, P., Granchi, D., Cavallazi, L., Santarelli, L. & Fabris, N. (1994) Plasma zinc level and thymic hormone activity in young cancer patients. Blood 83:749-757.

    Abstract/FREE Full Text

  48. ↵ 

    Mossad, S. B., Macknin, M. L., Medendorp, M.P.H. & and Mason, P. (1996) Zinc gluconate lozenges for treating the common cold. Ann. Intern. Med. 125:81-88.

    CrossRefMedline

  49. ↵ 

    Odeh, M. (1992) The role of zinc in acquired immunodeficiency syndrome. J. Intern. Med. 231:463-469.

    Medline

  50. ↵ 

    Pescovitz, M. D., Mehta, P. L., Jindal, R. M., Milgrom, M. L., Leapman, S. B. & Filo, R. S. (1996) Zinc deficiency and its repletion following liver transplantation in humans. Clin. Transplant. 10:256-260.

    Medline

  51. ↵ 

    Prasad, A. S. & Cossack, S.E.T. (1984) Zinc supplementation and growth in sickle cell disease. Ann. Intern. Med. 100:367-371.

  52. ↵ 

    Reddy, M. M., Sorrel, S. J., Lange, M. & Grieco, M. H. (1988) Tumor necrosis factor and HIV P24 antigen levels in serum of HIV-infected populations. J. Acquir. Defic. Syndr. 1:436-440.

  53. ↵ 

    Ripa, S. & Ripa, R. (1995) Zinc and immune function. Minerva Med 86:315-318.

     Medline

  54. ↵ 

    Rosenberg, Z. F. & Fauci, A. S. (1989) Immunopathogenic mechanisms of HIV infection. Clin. Immunol. Immunopathol. 50:149-156.

  55. ↵ 

    Rosenberg, Z. F. & Fauci, A. S. (1990) Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression. Immunol. Today 11:176-180.

    CrossRefMedline

  56. ↵ 

    Schlesinger, L., Arevalo, M., Arredondo, S., Lonnerdal, B. & Stekel, A. (1993) Zinc supplementation impairs monocyte function. Acta Paediatr 82:734-738.

    Medline

  57. ↵ 

    Smith, D. S., Helzner, E. C., Nuttall, C. E., Collins, M., Rofman, B. A. & Ginsberg, D. (1989) Failure of zinc gluconate in treatment of acute upper respiratory tract infections. Antimicrob. Agents Chemother. 33:646-648.

    Abstract/FREE Full Text

  58. ↵ 

    Swanson, C. A., Mansourian, R., Dirren, H. & Rapin, C. H. (1988) Zinc status of healthy elderly adults: response to supplementation. Am. J. Clin. Nutr. 48:343-349.

    Abstract/FREE Full Text

  59. ↵ 

    Tang, A. M., Graham, N. M., Kirby, A. J., McCall, L. D., Willett, W. C. & Saah, A. J. (1993) Dietary micronutrient intake and risk of progression to acquired immunodeficiency syndrome (AIDS) in human deficiency virus type 1 (HIV-1)-infected homosexual men. Am. J. Epidemiol. 138:937-951.

    Abstract/FREE Full Text

  60. ↵ 

    Tang, A. M., Graham, N.M.H. & Saah, A. J. (1996) Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection. Am. J. Epidemiol. 143:1244-1256.

    Abstract/FREE Full Text

  61. ↵ 

    Weismann, K., Jakobsen, J. P., Weismann, J. E., Hammer, U. M., Nyholm, S. M. & Hansen, B. (1990) Zinc gluconate lozenges for common cold. A double-blind clinical trial. Dan. Med. Bull. 37:279-281.

    Medline

  62. ↵ 

    Zarski, J. P., Arnaud, J., Labadie, H., Beaugrand, M., Favier, A. & Rachail, M. (1987) Evolution des concentrations seriques et tissulaires de zinc apres supplementation orale chez des alcooliques chroniques avec et sans cirrhose. [Serum and tissue concentrations of zinc after oral supplementation in chronic alcoholics with or without cirrhosis.]. Gastroenterol. Clin. Biol. 11:856-860 (in French).

    Medline

  63. ↵ 

    Zheng, R., Jenkins, T. M. & Craigie, R. (1996) Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc. Natl. Acad. Sci. U.S.A. 93:13659-13664. Abstract/FREE Full Text